SUMATRIPTAN-D6 HEMISUCCINATE

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H318：Verursacht schwere Augenschäden.

• Sicherheit

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

  P310：Sofort GIFTINFORMATIONSZENTRUM/Arzt/ anrufen.

SUMATRIPTAN-D6 HEMISUCCINATE Chemische Eigenschaften,Einsatz,Produktion Methoden

• Biologische Aktivität

  Sumatriptan-d6 is intended for use as an internal standard for the quantification of sumatriptan by GC- or LC-MS. Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).1 It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125743 and GR127935 . Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.2 Formulations containing sumatriptan have been used in the treatment of migraine headache.

• Einzelnachweise

  1.Razzaque, Z., Heald, M.A., Pickard, J.D., et al.Vasoconstriction in human isolated middle meningeal arteries: Determining the contribution of 5-HT1B- and 5-HT1F-receptor activationBr. J. Pharmacol.47(1)75-82(1999) 2.Pradhan, A., Smith, M.L., McGuire, B., et al.Characterization of a novel model of chronic migrainePain155(2)269-274(2014)

SUMATRIPTAN-D6 HEMISUCCINATE Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(5)Suppliers